Raphael Chee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raphael Chee has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Cathy van de Graaf
University Medical Center Groningen Groningen The Netherlands
1 shared publication- Chloe Ayres
Department of Obstetrics and Gynaecology, King Edward Memorial Hospital Women's and Newborns Health Service Perth Australia
1 shared publication E. Leong
GenesisCare Murdoch Perth WA Australia
1 shared publication- Elizabeth Nathan
Department of Biostatistics, Women and Infants Research Foundation, KEM Hospital for Women, Perth, Australia
1 shared publication - Emma Rose Allanson
Division of Obstetrics and Gynaecology, The University of Western Australia—Perth Campus, Perth, Western Australia, Australia
1 shared publication - Erin Kelty
Perth Western Australia 6009 The University of Western Australia School of Population and Global Health
1 shared publication
Latest Publications
- 18 November 2026
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 66 (6)
Patterns of Care in Patients With Cervical Cancer in Western Australia: A Retrospective Cohort Study
Background: Cervical cancer is an important public health concern with underserved populations having higher incidence and mortality. Aims: To examine associations between patient and tumour characteristics, receipt of appropriate treatment and survival. Materials and Methods: Retrospective cohort study of cervical cancer patients managed by the Western Australian Gynaecological Cancer Service from 1 January 2009 to 31 December 2018. Appropriate treatment was defined by international guidelines. Univariable and multivariable analyses assessed associations between demographic and tumour factors and receipt of appropriate treatment. Survival outcomes were evaluated using multivariable Cox regression. Results: Of 526 patients included, 95.4% received treatment, of which 94.4% received appropriate treatment. Non‐English‐speaking patients had reduced odds of completing treatment (OR 0.28, 95% CI 0.10–0.80, p = 0.018), and patients of lower socioeconomic status had reduced odds of timely treatment (OR 0.57, 95% CI 0.35–0.93, p = 0.025). Patients aged over 60 years had lower odds of receiving any, complete and timely treatment. Those diagnosed between 2014 and 2018, versus 2009–2013 had increased odds of completing treatment (OR 3.08, 95% CI 1.45–6.45, p = 0.003). Higher disease stage was associated with lower odds of receiving and completing treatment. Overall‐ and disease‐free survival were poorer among patients aged over 60, those with advanced‐stage disease, those diagnosed in 2009–2013, and those who received incomplete treatment or no treatment. Conclusions: Most patients received appropriate treatment. Non‐English‐speaking patients, older patients, and those of low socioeconomic status were less likely to receive appropriate care. Older age, advanced disease stage, diagnosis in 2009–2013, and incomplete treatment were associated with poorer survival.
- 18 November 2026
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 66 (6)
Patterns of Care in Patients With Cervical Cancer in Western Australia: A Retrospective Cohort Study
Background: Cervical cancer is an important public health concern with underserved populations having higher incidence and mortality. Aims: To examine associations between patient and tumour characteristics, receipt of appropriate treatment and survival. Materials and Methods: Retrospective cohort study of cervical cancer patients managed by the Western Australian Gynaecological Cancer Service from 1 January 2009 to 31 December 2018. Appropriate treatment was defined by international guidelines. Univariable and multivariable analyses assessed associations between demographic and tumour factors and receipt of appropriate treatment. Survival outcomes were evaluated using multivariable Cox regression. Results: Of 526 patients included, 95.4% received treatment, of which 94.4% received appropriate treatment. Non‐English‐speaking patients had reduced odds of completing treatment (OR 0.28, 95% CI 0.10–0.80, p = 0.018), and patients of lower socioeconomic status had reduced odds of timely treatment (OR 0.57, 95% CI 0.35–0.93, p = 0.025). Patients aged over 60 years had lower odds of receiving any, complete and timely treatment. Those diagnosed between 2014 and 2018, versus 2009–2013 had increased odds of completing treatment (OR 3.08, 95% CI 1.45–6.45, p = 0.003). Higher disease stage was associated with lower odds of receiving and completing treatment. Overall‐ and disease‐free survival were poorer among patients aged over 60, those with advanced‐stage disease, those diagnosed in 2009–2013, and those who received incomplete treatment or no treatment. Conclusions: Most patients received appropriate treatment. Non‐English‐speaking patients, older patients, and those of low socioeconomic status were less likely to receive appropriate care. Older age, advanced disease stage, diagnosis in 2009–2013, and incomplete treatment were associated with poorer survival.
- 12 September 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
MRI ‐Guided SBRT Boost for Patients With Locally Advanced Cervical Cancer Who Are Unsuitable for Standard of Care Image‐Guided Brachytherapy
Introduction: In recent years, cervical cancer incidence has been on the decline in Australia, likely due to the HPV vaccination and an improved screening programme. However, an estimated 900 new cases will be diagnosed in 2025. The standard of care for locally advanced cervical cancer (LACC) is chemoradiotherapy, comprising external beam radiation therapy with concurrent cisplatin followed by image guided brachytherapy (IGBT), which is essential for optimal local control. Some patients will be ineligible for IGBT due to comorbidities, anaesthetic risk or technical challenges, with alternative EBRT boost techniques demonstrating higher toxicity and poorer patient outcomes. MR‐guided stereotactic body radiotherapy (MRg‐SBRT) offers improved soft tissue visualisation and daily adaptive planning, enabling accurate target coverage and reduced dose to organs at risk. MRg‐SBRT is an investigational non‐invasive boost option with emerging evidence supporting feasibility Methods: We describe our early experience treating four patients with cervical cancer who were ineligible for IGBT following pelvic EBRT ± chemotherapy. All patients completed treatment with adaptive MRg‐SBRT. Results: Median high‐risk clinical target volume (HR‐CTV) D98% was 78.7 Gy EQD2 10 , demonstrating adequate target coverage. Early imaging showed one complete response, one local progression and one combined local and metastatic progression. Acute toxicities were predominantly Grade 1, with one case of Grade 3 pelvic pain and no Grade 4 events. Conclusions: MRg‐SBRT boost was feasible and well tolerated, achieving reasonable dose escalation with acceptable toxicity, representing a potential alternative for patients' ineligible for brachytherapy. Trial Registration: MARGARITA Protocol, NCT05937958
- 12 September 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
MRI ‐Guided SBRT Boost for Patients With Locally Advanced Cervical Cancer Who Are Unsuitable for Standard of Care Image‐Guided Brachytherapy
Introduction: In recent years, cervical cancer incidence has been on the decline in Australia, likely due to the HPV vaccination and an improved screening programme. However, an estimated 900 new cases will be diagnosed in 2025. The standard of care for locally advanced cervical cancer (LACC) is chemoradiotherapy, comprising external beam radiation therapy with concurrent cisplatin followed by image guided brachytherapy (IGBT), which is essential for optimal local control. Some patients will be ineligible for IGBT due to comorbidities, anaesthetic risk or technical challenges, with alternative EBRT boost techniques demonstrating higher toxicity and poorer patient outcomes. MR‐guided stereotactic body radiotherapy (MRg‐SBRT) offers improved soft tissue visualisation and daily adaptive planning, enabling accurate target coverage and reduced dose to organs at risk. MRg‐SBRT is an investigational non‐invasive boost option with emerging evidence supporting feasibility Methods: We describe our early experience treating four patients with cervical cancer who were ineligible for IGBT following pelvic EBRT ± chemotherapy. All patients completed treatment with adaptive MRg‐SBRT. Results: Median high‐risk clinical target volume (HR‐CTV) D98% was 78.7 Gy EQD2 10 , demonstrating adequate target coverage. Early imaging showed one complete response, one local progression and one combined local and metastatic progression. Acute toxicities were predominantly Grade 1, with one case of Grade 3 pelvic pain and no Grade 4 events. Conclusions: MRg‐SBRT boost was feasible and well tolerated, achieving reasonable dose escalation with acceptable toxicity, representing a potential alternative for patients' ineligible for brachytherapy. Trial Registration: MARGARITA Protocol, NCT05937958